Infectious disease revenue cycle management (RCM) involves coordinating coding accuracy, payer authorization management, infusion drug billing, and denial resolution across a patient population that often carries complex insurance profiles, dual coverage, and high per-visit claim values. The financial health of an infectious disease practice depends on maintaining AR days within the 28-32 day range, a standard that MMBS achieves for infectious disease clients compared to the specialty’s industry average of 42-50 days. This gap represents real dollars: a 10-physician infectious disease group billing $400,000 monthly that reduces AR days from 50 to 30 frees up roughly $133,000 in cash flow during the transition period alone.
Key Performance Indicators for Infectious Disease
Four KPIs define financial performance for infectious disease practices: net collection rate, clean claim rate, denial rate, and AR days. The net collection rate measures what the practice actually collects as a percentage of allowable charges after contractual adjustments. For infectious disease, a healthy net collection rate falls between 95% and 98%. The clean claim rate measures what percentage of claims pay on first submission without requiring manual intervention. Industry average for infectious disease sits around 88-90%; MMBS infectious disease clients average 97.1% on first submission. The denial rate tracks the percentage of submitted claims that are fully denied rather than partially adjusted. Industry average is 9%; MMBS clients operate at 3.2% net denial after appeals.
AR Aging Buckets and Revenue Leakage Points
AR aging in infectious disease concentrates in two buckets: 0-30 days (clearinghouse and payer processing) and 60-90 days (medical necessity and authorization denials). Claims that age past 90 days are at significant risk of timely filing exclusion, particularly for commercial payers with 90-day filing windows. Revenue leakage in infectious disease occurs at four points: uncoded infusion time (nursing staff stop-time documentation errors), under-coded E/M visits (selecting 99213 when 99215 is supported), unbilled J-codes for drugs administered but not billed, and missed prior authorization renewals on long-course IV therapy. Each leakage point is addressable with a targeted process change.
Infusion Revenue Optimization
Infusion billing represents a disproportionately large share of infectious disease revenue. A single course of outpatient IV ceftriaxone for Lyme disease billed under CPT 96365 and J0696 can generate $80-200 per visit depending on payer and duration. Ensuring complete infusion documentation (drug, dose, route, time in, time out) and accurate J-code billing prevents the most common revenue leak in this service line. Some practices lose 8-12% of infusion revenue to unbilled or underbilled drug costs when clinical staff do not document the exact drug quantity administered.
Payer Mix and Reimbursement Impact
Infectious disease payer mix significantly affects revenue cycle performance. Practices with high Medicare volume face consultation code restrictions (99241-99245 not reimbursable), which reduces revenue per consult encounter compared to commercial payer rates. Practices in regions with high Medicaid volume encounter longer authorization timelines and lower fee schedule rates for infusion services. MMBS analyzes payer mix quarterly for infectious disease clients, flagging contract rate shortfalls and identifying opportunities to renegotiate commercial rates based on clean claim performance data.
MMBS Performance Benchmarks vs Industry
The table below compares industry average RCM metrics for infectious disease practices against MMBS client averages, based on internal performance data from practices billing across all 50 states.